Electrophysiological effects of ULFS 49 CL

  • K. Seidl
  • B. Hauer
  • W. Lengfelder
  • J. Senges
Conference paper


Pharmacologically, a decrease in sinus heart rate can be achieved by several means: indirectly, via inhibition of the autonomic nervous system, and directly at the pacemaker cells of the atrial sinus node. The term “Specific Bradycardic Agents” has been proposed for drugs which directly decrease the sinus rate in doses or concentrations smaller than are necessary to elicit other pharmacological effects [1, 7, 9, 10, 13]. ULFS 49 CL is such a new, specific, negative chronotropic agent which directly decreases the spontaneous heart rate by slowing the diastolic depolarization of the pacemaker cells in the sinu-atrial node [6, 8, 11].


Pacemaker Cell Effective Refractory Period Diastolic Depolarization Organic Heart Disease Sinus Node Recovery Time 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bouman LN, Ginneken A van, Opthof T, Duivenvoorden JJ (1986) Electrophysiology of sinoatrial node and the action of specific bradycardic agents (SBA), a novel approach to cardiac physiology and therapy. International workshop at the Ernst Boehringer Institut, Bender u. CoGoogle Scholar
  2. 2.
    Buckberg GD, Fixier DE, Archie JP, Hoffman JIE (1972) Experimental subendocardial ischemia in dogs with normal coronary arteries. Circ Res, 30: 67–81PubMedGoogle Scholar
  3. 3.
    Buckberg GD, Fixier DE, Archie JP, Henney RP, Hoffman JIE (1975) Variable effects of heart rate on phasic and regional left ventricular muscle blood flow in anesthetized dogs. Cardiovasc Res 9: 1–11PubMedCrossRefGoogle Scholar
  4. 4.
    Connoly ME, Kersting F, Dollery CT (1976) The clinical pharmacology of beta-adrenergic blocking drugs. Prog Cardiovasc Dis 19: 203–49CrossRefGoogle Scholar
  5. 5.
    Dämmgen JW, Lamping KA, Gross GJ (1985) Action of two new bradycardic agents, AQ-AH 208 and ULFS 49, on ischemic myocardial perfusion and function. J Cardiovasc Pharmacol 7: 71–79PubMedCrossRefGoogle Scholar
  6. 6.
    Gruber R, Lumper G, Zilberszac A, Heistracher P (1983) Effects of ULFS 49 CL on the action potential of the guinea-pig heart. Naunyn-Schmiedeberg’s Arch. Pharmacol. 324, R 32Google Scholar
  7. 7.
    Heistracher P (1986) Specific bradycardic agents: Introduction; specific bradycardic agents, a novel approach to cardiac physiology and therapy. International workshop at the Ernst-Boehringer-Institut, Bender u. CoGoogle Scholar
  8. 8.
    Kobinger W, Lillie C (1984a) Cardiovascular characterization of ULFS 49 CL, a new “specific bradycardic agent”. Eur. J. Pharmacol. 104: 9–18PubMedCrossRefGoogle Scholar
  9. 9.
    Kobinger W, Lillie C (1984b) New Drugs Annual: Cardiovascular Drugs, Vol. 2, Chapter 10, 193–210, ed. by Alexander Scriabine, Raven Press, New YorkGoogle Scholar
  10. 10.
    Kobinger W (1985) Specific bradycardic agents, a new approach to therapy in angina pectoris? Prog Pharmacol 5 (3), 89–100Google Scholar
  11. 11.
    Lillie C, Kobinger W (1983) Cardiovascular actions of ULFS 49, a new “specific bradycardic agent”, Naunyn-Schmiedeberg’s Arch. Pharmacol. 324, R 33Google Scholar
  12. 12.
    Mc Allister RG Jr. (1982) Clinical pharmacology of slow channel calcium blocking agents. Prog Cardiovasc Dis 25: 83–102CrossRefGoogle Scholar
  13. 13.
    Reiffen M (1985) Specific bradycardic agents—a new principle in coronary heart disease 189th ACS National Meeting, American Chemical Society, Division of Medical Chemistry Abstr 41Google Scholar
  14. 14.
    Senges Rizos I, Brachmann J, Anders G, Jauerning R, Hamman H-D, Kübler W (1983) Effect of nifedipine and AQ-A39 on the sinoatrial and atrioventricular nodes of the rabbit and their antiarrhythmic action on atrioventricular nodal reentrant tachycardia. Cardiovasc Res 17: 132–144CrossRefGoogle Scholar
  15. 15.
    Sonnenblick EH; Skeleton CL (1971) Oxygen consumption of the heart: Physiological principles and clinical implications. Mod concepts Cardiovasc Dis 40, 9–16Google Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 1991

Authors and Affiliations

  • K. Seidl
    • 1
  • B. Hauer
    • 1
  • W. Lengfelder
    • 1
  • J. Senges
    • 1
  1. 1.Klinikum LudwigshafenLudwigshafen/RheinGermany

Personalised recommendations